A group from Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, etc. has reported on glycan profiling analysis of serum NRG1 in papillary thyroid cancer with using Lectin Microarrays.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798758/
This study is evaluating if BRAF V600E mutant status in papillary thyroid cancer (PTC) patients could be detected by analyzing multiple glycan profiles of serum NRG1 through lectin microarray assays.
It has been reported that NRG1 overexpression was related in various cancers. NRG1 protein can bind to ERBB3 or ERBB4 protein, activating ERBB receptor tyrosine kinases, followed by the initiation of signal cascades, including PI3K/AKT pathways. NRG1 can be secreted to serum as reported.
lectin microarrays were used to analyze the different glycan profiles of NRG1 from sera of BRAF(+) PTC and BRAF wild type(-) PTC patients. Lectin microarray is a rapid and sensitive high-throughput technique to get glycan profiles, allowing researchers to directly analyze glycoproteins without liberation of glycans from the core substrate.
It was found that LEL, BPL and NML tended to have bound to NRG1 in BRAF(+) PTC patients compared to BRAF(-) controls.
